|
JP6929792B2
(ja)
|
2015-02-16 |
2021-09-01 |
ザ ユニバーシティ オブ クィーンズランド |
スルホニル尿素及び関連化合物並びにその使用
|
|
EP3365724B1
(en)
|
2015-10-20 |
2021-05-05 |
Magic Leap, Inc. |
Selecting virtual objects in a three-dimensional space
|
|
CA3018758A1
(en)
|
2016-03-31 |
2017-10-05 |
Magic Leap, Inc. |
Interactions with 3d virtual objects using poses and multiple-dof controllers
|
|
UA126675C2
(uk)
|
2017-01-23 |
2023-01-11 |
Дженентек, Інк. |
Хімічні сполуки як інгібітори активності інтерлейкіну-1
|
|
US10768693B2
(en)
|
2017-04-19 |
2020-09-08 |
Magic Leap, Inc. |
Multimodal task execution and text editing for a wearable system
|
|
CN110914256A
(zh)
|
2017-07-07 |
2020-03-24 |
英夫拉索姆有限公司 |
新颖磺酰胺羧酰胺化合物
|
|
US11370763B2
(en)
|
2017-07-24 |
2022-06-28 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
JP7412328B2
(ja)
*
|
2017-07-24 |
2024-01-12 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
MX2020001776A
(es)
*
|
2017-08-15 |
2020-03-24 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
|
|
WO2019034693A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
|
|
TW201910317A
(zh)
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
ES2927851T3
(es)
|
2017-10-17 |
2022-11-11 |
Novartis Ag |
Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
|
|
CN111315733A
(zh)
|
2017-11-09 |
2020-06-19 |
英夫拉索姆有限公司 |
新颖磺酰胺甲酰胺化合物
|
|
WO2019092171A1
(en)
|
2017-11-09 |
2019-05-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
US11834433B2
(en)
|
2018-03-02 |
2023-12-05 |
Inflazome Limited |
Compounds
|
|
GB201803394D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166619A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166632A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
US11884645B2
(en)
|
2018-03-02 |
2024-01-30 |
Inflazome Limited |
Sulfonyl acetamides as NLRP3 inhibitors
|
|
US20200399242A1
(en)
*
|
2018-03-02 |
2020-12-24 |
Inflazome Limited |
Novel compounds
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
US12168653B2
(en)
|
2018-03-02 |
2024-12-17 |
Inflazome Limited |
Sulfonamide derivates as NLRP3 inhibitors
|
|
EP3759090A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
CR20200588A
(es)
|
2018-05-04 |
2021-06-24 |
Inflazome Ltd |
Compuestos novedosos
|
|
JP2021529780A
(ja)
|
2018-07-03 |
2021-11-04 |
ノバルティス アーゲー |
Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
|
|
US20210395241A1
(en)
|
2018-07-03 |
2021-12-23 |
Novartis Ag |
Nlrp modulators
|
|
MX2021000660A
(es)
|
2018-07-20 |
2021-03-25 |
Hoffmann La Roche |
Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
|
|
MA53172A
(fr)
|
2018-07-20 |
2021-05-26 |
Hoffmann La Roche |
Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
|
|
SG11202101480XA
(en)
|
2018-08-15 |
2021-03-30 |
Inflazome Ltd |
Novel sulfonamideurea compounds
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
JP2022505562A
(ja)
*
|
2018-10-24 |
2022-01-14 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
CN113015730A
(zh)
*
|
2018-11-13 |
2021-06-22 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
CN113166081A
(zh)
*
|
2018-11-13 |
2021-07-23 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
EP3880658A1
(en)
*
|
2018-11-16 |
2021-09-22 |
Novartis AG |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
US20220227707A1
(en)
*
|
2019-01-22 |
2022-07-21 |
Novartis Ag |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
WO2020249669A1
(en)
*
|
2019-06-12 |
2020-12-17 |
NodThera Limited |
Sulfonamide derivatives and uses thereof
|
|
CN114008030A
(zh)
|
2019-06-21 |
2022-02-01 |
Ac免疫有限公司 |
用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
|
|
AU2020312800B2
(en)
|
2019-07-17 |
2026-04-23 |
Zomagen Biosciences Ltd |
N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
|
|
WO2021009567A1
(en)
*
|
2019-07-17 |
2021-01-21 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
JP2022545407A
(ja)
*
|
2019-08-16 |
2022-10-27 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤として有用な大環状スルホニルアミド誘導体
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
BR112022014480A2
(pt)
|
2020-01-22 |
2022-09-13 |
Hoffmann La Roche |
Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
CA3175729A1
(en)
|
2020-03-16 |
2021-09-23 |
Zomagen Biosciences Ltd |
Nlrp3 modulators
|
|
CN121177307A
(zh)
*
|
2020-03-19 |
2025-12-23 |
南洋理工大学 |
包含nlrp1炎性体激活抑制剂的化合物或组合物用于治疗人气道炎症的用途
|
|
CN115279739B
(zh)
*
|
2020-03-27 |
2025-07-22 |
尼科治疗有限公司 |
取代哒嗪化合物
|
|
CN111419842A
(zh)
*
|
2020-04-24 |
2020-07-17 |
南方医科大学南方医院 |
炎症小体抑制剂cy-09用于制备治疗非酒精性脂肪性肝炎的药物的用途
|
|
CN115768749B
(zh)
*
|
2020-06-11 |
2024-04-19 |
辰欣药业股份有限公司 |
二甲基亚磺酰亚胺衍生物
|
|
US12624010B2
(en)
|
2020-06-19 |
2026-05-12 |
Ac Immune Sa |
Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
|
|
WO2022022646A1
(zh)
*
|
2020-07-29 |
2022-02-03 |
南京明德新药研发有限公司 |
含硒五元杂芳环化合物
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
WO2022230912A1
(ja)
|
2021-04-28 |
2022-11-03 |
アステラス製薬株式会社 |
置換トリアジン化合物
|
|
CA3226995A1
(en)
|
2021-07-21 |
2023-01-26 |
Nico Therapeutics, Inc. |
Annulated pyridazine compound
|
|
JP2025502732A
(ja)
|
2021-12-22 |
2025-01-28 |
エーシー・イミューン・エス・アー |
ジヒドロオキサゾール誘導体化合物
|
|
CN114213358A
(zh)
*
|
2021-12-22 |
2022-03-22 |
上海泰坦科技股份有限公司 |
一种2-溴-5-甲醛基噻唑的合成方法
|
|
JP2025524640A
(ja)
|
2022-07-14 |
2025-07-30 |
エーシー・イミューン・エス・アー |
Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
|
|
WO2024023266A1
(en)
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
Novel compounds
|
|
CN120152974A
(zh)
|
2022-10-26 |
2025-06-13 |
天维生物制药有限公司 |
缩环哒嗪衍生物
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
PE20252770A1
(es)
*
|
2023-03-17 |
2025-12-22 |
Ventus Therapeutics U S Inc |
Derivados de amida para inhibir nlrp3 y usos de estos
|
|
AU2024280075A1
(en)
|
2023-06-02 |
2025-12-11 |
Merck Sharp & Dohme Llc |
5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
TW202545527A
(zh)
|
2024-01-16 |
2025-12-01 |
英商諾得瑟拉公司 |
Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
|
|
CN122555708A
(zh)
|
2024-01-17 |
2026-08-11 |
Ac免疫有限公司 |
用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
|
|
CN122555707A
(zh)
|
2024-01-17 |
2026-08-11 |
Ac免疫有限公司 |
用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|
|
WO2026132518A1
(en)
|
2024-12-20 |
2026-06-25 |
Ac Immune Sa |
Heterocyclic compounds modulating the nlrp3 inflammasome pathway
|